Key facts
- Pacira BioSciences is urging stockholders to vote for its nominated directors.
- The company warns that electing DOMA nominees could compromise its momentum.
- Independent experts ISS, Glass Lewis, and Egan-Jones agree DOMA representation is not warranted.
Pacira BioSciences, Inc. (Nasdaq: PCRX) is reminding its stockholders to vote the BLUE proxy card in favor of the company's highly qualified nominees ahead of its upcoming annual meeting. The company asserts that the election of even a single nominee from DOMA would risk compromising Pacira's strong forward momentum. Pacira highlighted that independent leading experts, including ISS, Glass Lewis, and Egan-Jones, all agree that DOMA representation is not warranted. The company is based in Brisbane, California.